Abstract
Background: The effect of a bolus dose of dexmedetomidine on intraoperative neuromonitoring (IONM) parameters during spinal surgeries has been variably reported and remains a debated topic. Methods: A randomized, double-blinded, placebo-controlled study was performed to assess the effect of dexmedetomidine (1 μg/kg in 10 min) followed by a constant infusion rate on IONM during thoracic spinal decompression surgery (TSDS). A total of 165 patients were enrolled and randomized into three groups: T group (control), D1 group (constant infusion), and D2 group (loading dose followed by infusion). Results: In the D2 group, within-group analysis showed suppressive effects on IONM parameters compared with baseline after a bolus dose. The D2 group also showed inhibitory effects compared with both the D1 and T groups, including a statistically significant decrease in SSEP and MEP amplitude and an increase in SSEP latency. No significance was found between the T and D1 groups. Conclusion: Dexmedetomidine delivered in a loading dose can significantly inhibit IONM parameters in TSDS. Special attention should be paid to the timing of a bolus dose; however, a constant infusion does not exert inhibitory effects.
Introduction
Thoracic spinal decompression surgery (TSDS) carries a high risk of permanent neurological injury or paralysis. To mitigate this, surgeons utilize Intraoperative Neuromonitoring (IONM), specifically Somatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP), to provide real-time feedback on spinal cord function.
Dexmedetomidine (DEX) is a common anesthetic adjuvant used to reduce opioid and propofol requirements. However, its impact on IONM signals is debated. If DEX suppresses these signals, it could lead to "false positives"—suggesting nerve damage that isn't occurring—potentially causing surgeons to halt necessary procedures. This study investigates whether the administration method (a rapid loading dose versus a slow constant infusion) is the deciding factor in signal interference.
Methods and Patient Cohort
The researchers conducted a randomized, double-blinded, placebo-controlled trial with 165 patients undergoing TSDS. All patients received Total Intravenous Anesthesia (TIVA) using propofol and remifentanil.
Patients were randomized into three groups:
- T Group (Control): Received a saline bolus and saline infusion.
- D1 Group: Received a saline bolus followed by a constant DEX infusion (0.5 μg/kg/h).
- D2 Group: Received a DEX loading dose (1 μg/kg over 10 min) followed by a constant infusion (0.5 μg/kg/h).
The team measured SSEP and MEP at multiple time points, starting from a baseline before drug administration through the end of surgery, focusing on changes in amplitude (signal strength) and latency (signal speed).
Key Results
The study revealed that the method of delivery is critical to maintaining IONM integrity. The most significant finding was that the rapid loading dose (bolus) in the D2 group caused transient but significant signal suppression, while the constant infusion in the D1 group did not.
MEP and SSEP Suppression
In the D2 group, SSEP latency increased by 5.50%, and SSEP amplitude decreased by 24.75% compared to baseline. Furthermore, the D2 group saw a 27.13% decrease in MEP amplitude shortly after the loading dose was administered.
These suppressive effects in the D2 group were statistically significant compared to both the control (T) and constant infusion (D1) groups. Crucially, the D1 group showed no significant difference in signals compared to the control group, suggesting that a constant infusion of 0.5 μg/kg/h is a "safe zone" for neuromonitoring.
Discussion and Clinical Implications
The suppressive window in the D2 group (approximately 10–25 minutes) often coincides with the start of surgical decompression—the exact moment when clear IONM signals are most vital. DEX likely inhibits synaptic transmission by activating the descending noradrenergic system, leading to postsynaptic hyperpolarization. A high-concentration bolus triggers this effect much more intensely than a steady, low-level infusion.
Additionally, the loading dose caused short-lived hemodynamic instability, including drops in Mean Arterial Pressure (MAP) and Heart Rate (HR). While the study was limited by its narrow age demographic (18–60 years) and the frequency of MEP recordings, the results provide clear guidance for clinical practice.
Conclusion
Dexmedetomidine is a useful anesthetic adjuvant, but its delivery timing is critical. A loading dose can inhibit IONM parameters enough to approach clinical warning criteria, potentially triggering false alarms. To avoid interference with neurological monitoring during critical phases of spinal surgery, clinicians should favor constant infusion over bolus administration.
Summary updated